Using protein-ligand docking to assess the chemical tractability of inhibiting a protein target

Journal of Molecular Modeling

Volumn 16, Issue 12, 2010, Pages 1833-1843

  Ward, Richard A ^a  

^a NONE

Author keywords

Druggability; Ligandability; Protein ligand docking

Indexed keywords

PROTEIN INHIBITOR;

ARTICLE; BINDING AFFINITY; BINDING SITE; CALCULATION; CHEMICAL BOND; COMPUTER MODEL; CRYSTAL STRUCTURE; DRUG SPECIFICITY; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN BINDING; STRUCTURE ANALYSIS; TECHNIQUE; X RAY CRYSTALLOGRAPHY;

ALGORITHMS; BINDING SITES; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; LIGANDS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION MAPPING; PROTEINS;

EID: 79951774159     PISSN: 16102940     EISSN: 09485023     Source Type: Journal    
DOI: 10.1007/s00894-010-0683-y     Document Type: Article

References (31)

1. Brown D, Superti-Furga G (2003) Rediscovering the sweet spot in drug discovery. Drug Discov Today 8:1067-1077 (Pubitemid 38124472)
2. Hajduk PJ, Huth JR, Fesik SW (2005) Druggability indices for protein targets derived from NMR-based screening data. J Med Chem 48:2518-2525 (Pubitemid 40516441)
3. Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Disc 1:727-730 (Pubitemid 37361545)
4. Hajduk PJ, Huth JR, Tse C (2005) Predicting protein druggability. Drug Discov Today 10(23-24):1675-1682 (Pubitemid 41817616)
5. Burgoyne NJ, Jackson RM (2006) Predicting protein interaction sites: binding hot-spots in protein-protein and protein-ligand interfaces. Bioinformatics 22:1335-1342 (Pubitemid 43985269)
6. Fuller JC, Burgoyne NJ, Jackson RM (2009) Predicting druggable binding sites at the protein-protein interface. Drug Discov Today 14(3-4):155-161
7. Cheng AZ, Coleman RG, Smyth KT, Cao Q, Soulard P, Caffrey DR, Salzberg AZ, Huang ES (2007) Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotechnol 25:71-75 (Pubitemid 46087905)
8. Jhoti H (2001) High-throughput structural proteomics using x-rays. Trends Biotechnol 19:67-71
9. Koshland DE (1958) Application of a theory of enzyme specificity to protein synthesis. Proc Natl Acad Sci 44:98-104
10. Whitty A, Kumaravel G (2006) Between a rock and a hard place? Nat Chem Biol 2:112-118 (Pubitemid 44323856)
11. Albert JS, Blomberg N, Breeze AL, Brown AJH, Burrows JN, Edwards PD, Folmer RHA, Geschwindner S, Griffen EJ, Kenny PW, Nowak T, Olsson LL, Sanganee H, Shapiro AB (2007) An integrated approach to fragment-based lead generation:philosophy, strategy and case studies from AstraZeneca's drug discovery programmes. Curr Top Med Chem 7:1600-1629 (Pubitemid 350131017)
12. Congreve M, Carr R, Murray C, Jhoti HA (2008) 'Rule of Three' for fragment-based lead discovery? Drug Discov Today 8(Issue 19):876-877
13. Kim R, Skolnick J (2008) Assessment of programs for ligand binding affinity prediction. J Comput Chem 8:1316-1331 (Pubitemid 351594477)
14. Lipinski CA (1997) Adv Drug Del Rev 23:3-25
15. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The protein data bank. Nucleic Acids Res 28:235-242 (Pubitemid 30047768)
16. Maestro; Schrödinger: San Diego, CA 92122-1003
17. Hooft RWW, Sander C, Vriend G (1996) Proteins 26:363-376
18. Halgren T (2007) New method for fast and accurate binding-site identification and analysis. Chem Biol Drug Des 69(2):146-148 (Pubitemid 46457523)
19. Lyne PD, Kenny PW, Cosgrove DA, Deng C, Zabludoff S, Wendoloski JJ, Ashwell S (2004) Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening. J Med Chem 47:1962-1968 (Pubitemid 38453915)
20. CORINA; Gasteiger Research; Erlangen, Germany
21. Halgren T (1996) A Merck molecular force field: I-V. J Comput Chem 17:490-641
22. Grant JA, Pickup BT, Sykes MJ, Kitchen CA, Nicholls A (2007) Chem Phys Lett 441:163-166
23. GLIDE (Version 50207); Schrödinger: San Diego, CA 92122-1003
24. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 6:844-848 (Pubitemid 38174664)
25. JMP, Version 6. SAS Institute Inc., Cary, NC, 1989-2007
26. Buchanan SG (2003) Protein structure: discovering selective protein kinase inhibitors. Targets 2:101-108 (Pubitemid 40418168)
27. Roujeinikova A, Levy CW, Rowsell S, Sedelnikova S, Baker PJ, Minshull CA, Mistry A, Colls JG, Camble R, Stuitje AR, Slabas AR, Rafferty JB, Pauptit RA, Viner R, Rice DW (1999) Crystallographic analysis of triclosan bound to enoyl reductase. J Mol Biol 294:527-535
28. Zhang S, Zhang ZY (2007) PTP1B as a drug target: recent developments in PTP1B inhibitor discovery. Drug Discov Today 12:373-81 (Pubitemid 46636379)
29. Wiesmann C, Barr KJ, Kung J, Zhu J, Shen W, Fahr BJ, Zhong M, Taylor L, Randal M, McDowell RS, Hansen SK (2004) Allosteric inhibition of protein tyrosine phosphatase 1B. Nat Struct Mol Biol 11:730-737 (Pubitemid 39014498)
30. Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Järvinen T, Savolainen J (2008) Prodrugs: design and clinical applications. Nat Rev Drug Discovery 7:255-270 (Pubitemid 351324639)
31. Leeson PD, Springthorpe B (2007) The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discovery 6:881-890 (Pubitemid 350042396)